![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Kaplan-Meier Estimates of Disease-free Survival and Overall Survival in... | Download Scientific Diagram Kaplan-Meier Estimates of Disease-free Survival and Overall Survival in... | Download Scientific Diagram](https://www.researchgate.net/publication/329812426/figure/fig2/AS:710605988184067@1546433078461/Kaplan-Meier-Estimates-of-Disease-free-Survival-and-Overall-Survival-in-the.png)
Kaplan-Meier Estimates of Disease-free Survival and Overall Survival in... | Download Scientific Diagram
![Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804919307488-gr1.jpg)
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma | PLOS ONE
![Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram](https://www.researchgate.net/publication/233746224/figure/fig2/AS:601587995136000@1520441163001/Progression-free-survival-and-overall-survival-curves-for-all-patients-with-different.png)
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
![Comparison Overall survival and Disease free survival graph between two... | Download Scientific Diagram Comparison Overall survival and Disease free survival graph between two... | Download Scientific Diagram](https://www.researchgate.net/publication/349735701/figure/fig3/AS:1000346163879938@1615512519832/Comparison-Overall-survival-and-Disease-free-survival-graph-between-two-groups-A-The.png)
Comparison Overall survival and Disease free survival graph between two... | Download Scientific Diagram
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/2cbba9be-95f0-4764-ad55-25b5e2074383/gr1.gif)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma | Haematologica
![Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram](https://www.researchgate.net/publication/273956724/figure/fig2/AS:282745193418754@1444423115791/Comparison-of-disease-free-survival-DFS-and-overall-survival-OS-according-to-the.png)
Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram
![Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study | SpringerLink Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05966-y/MediaObjects/10549_2020_5966_Fig2_HTML.png)
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study | SpringerLink
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F1.large.jpg)
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
![Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/0/00c7385e94688a19921c14a15730ba55e0e5dd17.png)